Mochida Pharmaceutical Co., Ltd. Stock

Equities

4534

JP3922800002

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-05-24 am EDT 5-day change 1st Jan Change
2,955 JPY -0.07% Intraday chart for Mochida Pharmaceutical Co., Ltd. -3.27% -9.63%
Sales 2024 103B 655M Sales 2025 * 106B 675M Capitalization 105B 668M
Net income 2024 4.55B 28.96M Net income 2025 * 5.9B 37.57M EV / Sales 2024 1.11 x
Net cash position 2024 * 62.97B 401M Net cash position 2025 * 64.14B 408M EV / Sales 2025 * 0.38 x
P/E ratio 2024
25.4 x
P/E ratio 2025 *
17.8 x
Employees 1,529
Yield 2024
2.48%
Yield 2025 *
2.71%
Free-Float 53.94%
More Fundamentals * Assessed data
Dynamic Chart
Hidehiro Imatsu named president of Goldman Sachs Japan RE
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 1,080,000 shares, representing 2.97% for ¥3,485.1 million. CI
Mochida Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical's Fiscal Full-Year Profit Falls 37.1% MT
Mochida Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
More news
1 day-0.07%
1 week-3.27%
Current month-7.37%
1 month-5.14%
3 months-7.66%
6 months-10.59%
Current year-9.63%
More quotes
1 week
2 931.00
Extreme 2931
3 060.00
1 month
2 931.00
Extreme 2931
3 245.00
Current year
2 931.00
Extreme 2931
3 430.00
1 year
2 931.00
Extreme 2931
3 490.00
3 years
2 931.00
Extreme 2931
4 000.00
5 years
2 931.00
Extreme 2931
5 380.00
10 years
2 931.00
Extreme 2931
6 110.00
More quotes
Managers TitleAgeSince
President 65 91-03-31
Chief Administrative Officer 61 17-05-31
Chief Tech/Sci/R&D Officer 66 82-03-31
Members of the board TitleAgeSince
President 65 91-03-31
Director/Board Member 59 21-06-28
Director/Board Member 66 80-03-31
More insiders
Date Price Change Volume
24-05-24 2,955 -0.07% 30,900
24-05-23 2,957 -1.27% 35,100
24-05-22 2,995 -0.33% 44,000
24-05-21 3,005 -1.31% 36,700
24-05-20 3,045 -0.33% 35,400

Delayed Quote Japan Exchange, May 24, 2024 at 02:00 am EDT

More quotes
Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings